In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents — and many more are considering following suit. States cannot ...

Defensive blue-chip stock UnitedHealth is on a credible path back to double-digit growth next year, but is UNH a buy right ...

According to the notice, the product is the 12-pack "Destination Holiday Glow Light Stick Bracelets" that were sold in H-E-B ...

Get Q3 2025 insights from Novocure (NVCR): platform therapy expansion, profitability goals, earnings highlights, and cancer launch updates.

A new mRNA platform targets tumors with precision, limits side effects, and converts immune-silent cancers into responsive ...

It is often said that exercise is the best medicine, but for many older adults, it can be a prescription that is increasingly ...

Analysts have recently evaluated Warby Parker and provided 12-month price targets. The average target is $27.0, accompanied ...

D-Wave Quantum was the first company to commercialize cloud quantum services due to its annealing systems. Troy Jensen at Cantor Fitzgerald has set Rigetti with a target price of $18 ... He holds a ...

Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are ...

The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot flashes due to menopause.

Leverage was 3.31x, as calculated under our First Lien Credit Agreement at September 30, 2025. The results of the Community Living business are included in such calculation pursuant to our First Lien ...

Lynkuet (elinzanetant) may especially benefit some women with a history of breast cancer who are advised not to use hormone ...